Tardive dyskinesia risks

Tardive dyskinesia (risk increases with duration of treatment and with dose)... 

Immediately report the occurrence of the following adverse reactions restlessness, inability to sit still, muscle spasms, masklike expression, rigidity, tremors, drooling, or involuntary rhythmic movements of the mouth, face, or extremities. Inform all patients about the risks of extrapyramidal symptoms and tardive dyskinesia Avoid exposure to the sun. If exposure is unavoidable, wear sunblock, keep arms and legs covered, and wear a sun hat. 

Morgenstern, H. Glazer, W. M (1993). Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications results of the Yale Tardive Dyskinesia Study. Arch. Gen. Psychiatry, 50, 723-33. 

Ari pi prazole, olanzapine, quetiapine, risperidone, and ziprasidone are effective as monotherapy or as add-on therapy to lithium or valproate for acute mania. Prophylactic use of antipsychotics can be needed for some patients with recurrent mania or mixed states, but the risks versus benefits must be weighed in view of long-term side effects (e.g., obesity, type 2 diabetes, hyperlipidemia, hyperprolactinemia, cardiac disease, and tardive dyskinesia). 

Atypical Antipsychotics. The so-called atypical antipsychotics have revolutionized the treatment of schizophrenia and other psychotic disorders since their introduction in the 1990s. Similarly, they are replacing the older antipsychotics in the treatment of BPAD as well. They offer a similar degree of antimanic efficacy without a lessened long-term risk of tardive dyskinesia. For more information regarding the atypical antipsychotics, please refer to Chapter 4 Schizophrenia. 

Clozapine causes virtually no extrapyramidal side effects and can actually relieve tardive dyskinesia. Nevertheless, it is a difficult medication to tolerate. Its common side effects include drowsiness, weight gain, dizziness, constipation, and drooling (sialorrhea). Clozapine also increases the risk that vulnerable individuals may have seizures. 

Lithium (Eskaiith, Lithobid). Before the recent proliferation of atypical antipsychotics, lithium was tried as an alternative for schizophrenia. By and large, this represented another effort to circumvent the risk of tardive dyskinesia. It is not effective either as monotherapy or as combination therapy with antipsychotics in schizophrenia. 

Some researchers have investigated the notion of intermittent treatment. Patients are intensively monitored off medication, and a medication is started once prodromal signs of an impending acnte exacerbation are detected. One thought is that this minimizes the risk of side effects snch as tardive dyskinesia. Althongh in theory this may sound attractive, nnfortnnately, it rarely is successful in practice. Patients receiving intermittent treatment are at exceptionally high risk for relapse. 

In the residual phase, the patient is unlikely to have an acute exacerbation even if (s)he stops taking an antipsychotic. Nevertheless, (s)he may still require treatment for residual symptoms. If medications are continued during a residual phase of schizophrenia, an atypical antipsychotic is preferred. Because positive symptoms are no longer a prominent aspect of the illness, there is usually little justification for using a typical antipsychotic and thereby exposing a patient to the risk of tardive dyskinesia. Moreover, atypical antipsychotics likely better treat the remaining negative symptoms of residnal schizophrenia. 

Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics a systematic review of 1-year studies. Am J Psychiatry 2004 161 414-425. 

Antipsychotics also have a troublesome side effect burden that includes an often-irreversible movement disorder known as tardive dyskinesia (TD). Other side effects include so-called parkinsonism, dystonic reactions (i.e., abrupt onset of muscle spasms), akathisia (an uncomfortable sense of motoric restlessness), sedation, weight gain, dizziness, dry mouth, and constipation among others. These side effects, in particular the risk for TD, limit the usefulness of antipsychotics in the treatment of ADHD, and at this time the typical antipsychotics cannot be considered a reasonable monotherapy in uncomplicated ADHD. 

There are, of course, risks with long-term use of conventional antipsychotics. The most concerning is an irreversible movement disorder known as tardive dyskinesia. Nevertheless, some particularly fragile patients with BPD may require long-term antipsychotic treatment. If so, atypical antipsychotics are recommended. 

Tardive dyskinesia (TD) TD, a syndrome consisting of potentially irreversible, involuntary dyskinetic movements, may develop in patients treated with antipsychotic drugs. Both the risk of developing TD and the likelihood that it will become irreversible are increased as duration of treatment and total cumulative dose administered increase. 

EPS = extrapyramidal symptoms OH = orthostatic hypotension TD = tardive dyskinesia. These doses represent usually effective doses but individual patients may respond to lower or higher doses. Should be used rarely due to risk of bone marrow depression. 

---